Encapsulated cell therapy

• US 20060251630A1
• Filed: 12/24/2003
• Published: 11/09/2006
• Est. Priority Date: 12/24/2002
• Status: Abandoned Application

• Current Assignee: AN-Go-Gen Inc.
• Original Assignee: AN-Go-Gen Inc.
• Inventors: Stewart, Duncan J., Karoubi, Golnaz, Courtman, David
• Application Number:
  US10/540,743
• Publication Number:
  US 20060251630A1
• Time in Patent Office: Days
• US Class Current: 424/93.210
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 9/5036 Polysaccharides, e.g. gums, alginate; Cyclodextrin
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C12N 11/04 entrapped within the carrier, e.g. gel or hollow fibres
• CPC Class Codes: C12N 2533/52 Fibronectin; Laminin
• CPC Class Codes: C12N 2533/56 Fibrin; Thrombin
• CPC Class Codes: C12N 2533/76 Agarose, agar-agar
• CPC Class Codes: C12N 5/0656 Adult fibroblasts
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)

Abstract

Cell therapy comprises encapsulating a cell with an integrin or other cell interaction factor, for administration to a mammal. The cells may express a therapeutic transgene or the cells may be regenerative.

Claims

1-37. -37. (canceled)

38. A method of preparing a prepared cell, comprising encapsulating said cell in a cell encapsulation medium in vitro to form an encapsulation product for use in cell therapy in vivo, wherein said encapsulation product includes an integrin binding partner.

39. The method as claimed in claim 38, wherein said integrin binding partner is selected from the group consisting of collagen, Fibronectin, Fibrinogen, laminin, thrombospondin, vitronectin, factor X, C3bi, lg-like cell adhesion molecule (ICAM-1,2,3), type 1 collagen, vascular cell adhesion molecule (VCAM-1), mucosal addressin cell adhesion molecule-1 (MAdCAM-1), vitronectin, collagens, laminin, LFA, Mac-1, tenascin, von Willebrand factor, thrombospondin, factor X, FXll, FXllla, Arg-Gly-Asp, Leu-Asp-Val, His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val, an integrin binding partner containing the sequence Arg-Gly-Asp, Leu-Asp-Val, and an integrin binding partner containing the sequence His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val.

40. The method as claimed in claim 39, wherein said integrin binding partner is Fibrinogen.

41. The method as claimed in claim 39, wherein said integrin binding partner is Fibronectin.

42. The method as claimed in claim 41, wherein said encapsulation product is FXIII.

43. The method as claimed in claim 39, wherein said encapsulation product is FXIIIa.

44. The method as claimed in claim 39, wherein said integrin binding partner contains the recognition sequence argine-glycine-asparate (RGD).

45. The method as claimed in claim 38, wherein said integrin binding partner is bound to said prepared cell.

46. The method as claimed in claim 45, wherein said integrin binding partner is bound to said prepared cell prior to encapsulation.

47. The method as claimed in claim 38, wherein said integrin binding partner is not bound to said prepared cell.

48. The method as claimed in claim 38, wherein said integrin binding partner is in said cell encapsulation medium.

49. The method as claimed in claim 38, wherein said integrin binding partner is at the surface of said cell encapsulation medium.

50. The method as claimed in claim 38, wherein said cell encapsulation medium is selected from the group consisting of agarose with fibrin, agarose with Fibronectin, a combination of Fibronectin and Fibrinogen, plant-derived gums, alkali metal alginates and agarose, cellulose and its derivatives, gelatin, chitosan and extracellular matrix (ECM) components.

51. The method as claimed in claim 38, wherein said cell encapsulation medium is a natural polymer compatible with the survival and function of said cell.

52. The method as claimed in claim 38, wherein said cell encapsulation medium is a synthetic polymer compatible with the survival and function of said cell.

53. The method as claimed in claim 38, wherein most of said encapsulation product comprises one prepared cell per encapsulation.

56. The method as claimed in claim 38, wherein said cell encapsulation medium contains a transgene.

57. The method as claimed in claim 38, wherein said prepared cell contains a transgene.

58. The method as claimed in claim 57, wherein said transgene is incorporated into the cell subsequent to including a transgene in said encapsulation medium.

59. A method of providing cell therapy to a patient in need thereof, comprising administering the prepared cell of claim 38.

60. The method as claimed in claim 59, wherein said administration is intercardiac.

61. The method as claimed in claim 38, wherein said encapsulation product further comprises an external factor which can affect a host cell which is external to the encapsulation product.

62. The method as claimed in claim 61, wherein said external factor is selected from the group consisting of DCAM, ICAM and VCAM.

63. The method as claimed in claim 38, wherein said cell is selected from the group consisting of fibroblasts, endothelial cells, smooth muscle cells, progenitor/stem cells (e.g. from bone marrow, adipose, or peripheral blood), dermal fibroblasts, EPC (endothelial cells) or other mesenchymal cells, marrow stromal cells (MSC), and epithelial cells.

64. The method as claimed in claim 59, wherein said cell is selected from the group consisting of fibroblasts, endothelial cells, smooth muscle cells, progenitor/stem cells (e.g. from bone marrow, adipose, or peripheral blood), dermal fibroblasts, EPC (endothelial cells) or other mesenchymal cells, marrow stromal cells (MSC), and epithelial cells.

65. The method as claimed in claim 38, wherein said cell is selected from the group consisting of fibroblasts and bone marrow stromal cells.

66. The method as claimed in claim 59, wherein said cell is selected from the group consisting of fibroblasts and bone marrow stromal cells.

54. A method of preparing a prepared cell for use in vivo, comprising encapsulating said cell in a cell encapsulation medium in vitro to form an encapsulation product, wherein said encapsulation product includes an integrin binding partner, and wherein said encapsulation product contains one cell.

55. A method of preparing a prepared cell for storage or transportation for later use in vivo, comprising encapsulating said cell in a cell encapsulation medium in vitro to form an encapsulation product, wherein said encapsulation product includes an integrin binding partner.

67. A kit for cell based therapy in a mammal, comprising an effective amount of an integrin binding partner and instructions for the use thereof to prepare a cell encapsulation medium.

68. The kit as claimed in claim 67, wherein said instructions further describe administration of the cell based therapy to a patient in need thereof.

69. The kit as claimed in claim 68, wherein said instructions describe administration by cell based gene therapy.

70. The kit as claimed in claim 67, further comprising an encapsulation medium.

71. The kit as claimed in claim 69, wherein said instructions describe administration using viable, transfected mammalian cells, said transfected mammalian cells containing at least one expressible trans-gene coding for an apoptosis inhibitor.

72. The kit as claimed in claim 71, wherein said mammalian cells are selected from the group consisting of dermal fibroblasts, smooth muscle cells, progenitor cells, endothelial progenitor cells, epithelial progenitor cells, smooth muscle progenitor cells, stem cells, and endothelial cells.

73. The kit as claimed in claim 67, wherein said integrin binding partner is selected from the group consisting of collagen, Fibronectin, Fibrinogen, laminin, thrombospondin, vitronectin, factor X, C3bi, lg-like cell adhesion molecule (ICAM-1,2,3), type 1 collagen, vascular cell adhesion molecule (VCAM-1), mucosal addressin cell adhesion molecule-1 (MAdCAM-1), vitronectin, collagens, laminin, LFA, Mac-1, tenascin, von Willebrand factor, thrombospondin, factor X, FXlIl, FXllla, Arg-Gly-Asp, Leu-Asp-Val, His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val, an integrin binding partner containing the sequence Arg-Gly-Asp, Leu-Asp-Val, and an integrin binding partner containing the sequence His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val.

74. The kit according to claim 67, wherein said cell encapsulation medium is selected from the group consisting of agarose with fibrin, agrarose with Fibronectin, a combination of Fibronectin and Fibrinogen, plant-derived gums, alkali metal alginates and agarose, cellulose and its derivatives, gelatin, chitosan and extracellular matrix (ECM) components.